Select Medical (SEM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
4 Mar, 2026Executive summary
The 2026 Annual Meeting will be held virtually on April 23, 2026, with voting open to shareholders of record as of February 27, 2026.
Key proposals include director elections, executive compensation, auditor ratification, board declassification, and special meeting rights.
The Board recommends voting for all its proposals and against a shareholder proposal to lower the threshold for calling special meetings.
Voting matters and shareholder proposals
Election of three Class II directors, with terms dependent on approval of board declassification.
Advisory vote on executive compensation (say-on-pay).
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.
Proposal to phase out the classified board structure, moving to annual director elections by 2028.
Advisory vote to allow shareholders with 25% ownership to call special meetings (Board proposal).
Advisory vote on a shareholder proposal to allow 10% ownership threshold for special meetings (Board recommends against).
Board of directors and corporate governance
Board consists of ten directors, eight of whom are independent per NYSE standards.
Board diversity includes two women and one Asian director; regular review of board composition and diversity.
Lead Independent Director role established; board meets at least quarterly, with all directors attending at least 75% of meetings.
Corporate governance guidelines require directors to report changes in affiliations and offer resignation if requirements are not met.
Four standing committees: Audit and Compliance, Human Capital and Compensation, Nominating, and Quality of Care.
Latest events from Select Medical
- Merger and compensation proposals approved; official results to be filed on Form 8-K.SEM
AGM 2026 - Special meeting to vote on $16.50/share cash merger, with board and committee unanimous support.SEM
Proxy filing - Special Committee recommends approval of a $16.50/share going-private merger, offering an 18% premium.SEM
Proxy filing - Revenue up 5%, but net income and EBITDA fell; merger expected mid-2026, guidance maintained.SEM
Q1 2026 - Independent directors back $16.50/share going-private merger, with appraisal rights and executive pay vote.SEM
Proxy filing - Key votes include board structure changes, executive pay, and special meeting rights.SEM
Proxy Filing - Q3 2025 revenue up 7.2%, EPS up 21%, margins pressured, 2025 outlook reaffirmed.SEM
Q3 2025 - Q2 revenue up 5.1% to $1.76B; Concentra IPO raised $528.8M, reducing debt by $1.9B.SEM
Q2 2024 - Revenue, net income, and liquidity improved, with Concentra IPO and debt reduction as key highlights.SEM
Q3 2024